Association of the GGCX (CAA)16/17 repeat polymorphism with higher warfarin dose requirements in African Americans.
about
Clopidogrel and warfarin pharmacogenetic tests: what is the evidence for use in clinical practice?STRATEGIES FOR EQUITABLE PHARMACOGENOMIC-GUIDED WARFARIN DOSING AMONG EUROPEAN AND AFRICAN AMERICAN INDIVIDUALS IN A CLINICAL POPULATIONPathway analysis of genome-wide data improves warfarin dose prediction.Race influences warfarin dose changes associated with genetic factors.The future of warfarin pharmacogenetics in under-represented minority groups.Impact of GGCX, STX1B and FPGS Polymorphisms on Warfarin Dose Requirements in European-Americans and Egyptians.Pharmacogenomics of warfarin in populations of African descent.Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study.A pharmacogenetics service experience for pharmacy students, residents, and fellows.Does ethnicity play a role in the dosing of warfarin in Hawai'i?Optimal dosing of warfarin and other coumarin anticoagulants: the role of genetic polymorphisms.Genotype-guided coumarin dosing: where are we now and where do we need to go next?Warfarin Pharmacogenomics in Diverse Populations.Cohort-specific imputation of gene expression improves prediction of warfarin dose for African Americans.VKORC1-1639A allele influences warfarin maintenance dosage among Blacks receiving warfarin anticoagulation: a retrospective cohort study.Factors influencing pharmacokinetics of warfarin in African-Americans: implications for pharmacogenetic dosing algorithms.A new algorithm for weekly phenprocoumon dose variation in a southern Brazilian population: role for CYP2C9, CYP3A4/5 and VKORC1 genes polymorphisms.
P2860
Q26823542-73F60020-3631-47FF-BD18-AB799CBCC954Q33557032-A82510C2-AC99-491A-91BB-F6F35883123DQ34790566-B215B757-2F36-4742-B219-7705725BDEABQ35884265-1CA7F7EA-5155-413C-8777-ECACB39A9B6AQ36294461-0ADDC19E-5D79-4759-B339-8A7534251821Q36599219-B5F34429-CA4A-4639-B79D-13F337011559Q36629209-0B003788-238E-4442-B63A-601E78CF61E6Q37138272-28CCE023-0FD6-4B2E-9750-6F4E58FB6670Q37251749-38FBA927-7A51-471B-A318-2A8D8894F65CQ37654683-A05BEFF8-5FF8-485E-A859-B29358CBA20CQ38078754-91A3F146-BB5A-4D1C-9DEA-7189228BFC75Q38321269-9C023B60-94DC-4024-9A6C-3F61B34159EAQ38696567-CC678D26-C888-4259-8180-9B671003BE10Q46950581-0F6B6CEF-3BB8-4E62-BDB6-04F8A0C79906Q47345423-2A000615-B0A5-4030-BFA3-24D548023920Q50955265-EBCADA77-1285-4401-A702-25C5DF01BB3EQ51141937-B0E211DD-7A81-42D6-B857-A59EC4F81C5C
P2860
Association of the GGCX (CAA)16/17 repeat polymorphism with higher warfarin dose requirements in African Americans.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Association of the GGCX (CAA)1 ...... irements in African Americans.
@ast
Association of the GGCX (CAA)1 ...... irements in African Americans.
@en
type
label
Association of the GGCX (CAA)1 ...... irements in African Americans.
@ast
Association of the GGCX (CAA)1 ...... irements in African Americans.
@en
prefLabel
Association of the GGCX (CAA)1 ...... irements in African Americans.
@ast
Association of the GGCX (CAA)1 ...... irements in African Americans.
@en
P2093
P2860
P1476
Association of the GGCX (CAA)1 ...... irements in African Americans.
@en
P2093
Edith A Nutescu
Gelson Taube
Keston Aquino-Michaels
Larisa H Cavallari
Marlos A G Viana
Minoli Perera
Nancy L Shapiro
Shitalben R Patel
P2860
P304
P356
10.1097/FPC.0B013E32834F288F
P577
2012-02-01T00:00:00Z